| |
| |
|
| Insider
Information: |
Liu David Y |
| Relationship: |
Chief R&D Strategy Off... |
| City: |
Milpitas |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
167,590 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,962,340 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
167,590 |
|
|
| Total
Value |
$4,962,340 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Protagonist Therapeutics, Inc |
PTGX |
Chief R&D Strategy Off... |
2022-11-16 |
167,590 |
2017-07-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PTGX |
Protagonist Therapeutics,... |
Chief R&D Strategy Officer |
• – – |
2022-11-16 |
4 |
OE |
$0.87 |
$231,802 |
D/D |
100,479 |
167,590 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2022-02-28 |
4 |
D |
$24.28 |
$51,449 |
D/D |
(2,119) |
66,538 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
68,657 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2021-08-17 |
4 |
AS |
$47.56 |
$702,889 |
D/D |
(14,779) |
58,254 |
0 |
% |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2021-08-17 |
4 |
OE |
$0.87 |
$8,700 |
D/D |
10,000 |
73,033 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
62,427 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2019-08-06 |
4 |
S |
$8.85 |
$30,044 |
D/D |
(3,395) |
49,802 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2019-03-01 |
4 |
S |
$8.03 |
$6,504 |
D/D |
(810) |
51,197 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
52,007 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2019-02-06 |
4 |
S |
$7.74 |
$29,562 |
D/D |
(3,821) |
37,007 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
25,800 |
40,828 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-03-12 |
4 |
AS |
$21.29 |
$74,500 |
D/D |
(3,500) |
15,028 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-03-12 |
4 |
OE |
$4.21 |
$14,735 |
D/D |
3,500 |
18,528 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-03-02 |
4 |
AS |
$20.00 |
$17,500 |
D/D |
(875) |
13,322 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-03-02 |
4 |
OE |
$1.89 |
$1,654 |
D/D |
875 |
14,197 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,500 |
13,322 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-01-16 |
4 |
AS |
$20.00 |
$17,500 |
D/D |
(875) |
3,822 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2018-01-16 |
4 |
OE |
$1.89 |
$1,654 |
D/D |
875 |
4,697 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2017-12-18 |
4 |
AS |
$20.00 |
$17,500 |
D/D |
(875) |
3,822 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2017-12-18 |
4 |
OE |
$1.89 |
$1,654 |
D/D |
875 |
4,697 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2017-11-30 |
4 |
A |
$1.89 |
$1,654 |
D/D |
875 |
4,697 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2017-11-30 |
4 |
AS |
$20.00 |
$17,500 |
D/D |
(875) |
3,822 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2017-11-13 |
4 |
AS |
$16.97 |
$118,761 |
D/D |
(7,000) |
3,822 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2017-11-13 |
4 |
OE |
$1.89 |
$21,350 |
D/D |
7,000 |
7,322 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Scientific Officer |
• – – |
2017-08-28 |
4 |
AS |
$15.00 |
$52,500 |
D/D |
(3,500) |
2,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
